Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
Public ClinicalTrials.gov record NCT05643118. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of the Safety and Tolerability of OLX10212 in Patients With Neovascular Age-Related Macular Degeneration
Study identification
- NCT ID
- NCT05643118
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Olix Pharmaceuticals, Inc.
- Industry
- Enrollment
- 21 participants
Conditions and interventions
Conditions
Interventions
- OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA) Genetic
Genetic
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 3, 2023
- Primary completion
- Nov 24, 2024
- Completion
- Nov 9, 2025
- Last update posted
- Dec 10, 2025
2023 – 2025
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Retina Consultants | Santa Maria | California | 93434 | — |
| University Retina | Oak Forest | Illinois | 60452 | — |
| The Retina Institute | St Louis | Missouri | 63128 | — |
| Ophthalmic Consultants of the Capital Region | Troy | New York | 12180 | — |
| Texas Retina Consultants | Bellaire | Texas | 77401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05643118, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05643118 live on ClinicalTrials.gov.